Objectif Pharmacogenomics is an emerging discipline with a great potential for improving future clinical care. The linkage between the knowledge of treatment outcome and the underlying molecular alteration constitutes the principle of pharmacogenomics. The recent d evelopments of Herceptin (targeting the HER2 oncoprotein in breast cancer) and Glivec (targeting the BCR-ABL translocation in leukaemia) have demonstrated a close relationship between the molecular alteration and the clinical response. The success of these treatments has depended absolutely upon the development of appropriate clinical diagnostic tests (pharmacodiagnostics) to identify those patients, who are most likely to benefit from the treatment. The main objective of the proposed industry-academia part nership is to develop newpharmacodiagnostics to improve the selection of patients for targeted cancer therapies. DakoCytomation is a company at the forefront of the development of pharmacodiagnostics as evidenced by their strong involvement in ER and HER2. Dr. Bartlett research group at Glasgow University has achieved a unique expert position by combining translational research with histopathological evaluation of novel targeted cancer therapies tested by the pharmaceutical industry in European clinical tri als. Through exchange of experienced researchers, it is the intention to extend substantially the existing collaboration between DakoCytomation and Dr. Bartlett research group. This efficient way of combining complementary skills makes the objective very r ealistic. The new pharmacodiagnostic assays will be based on a) combining and optimising existing detection principles, b) combining detection of existing and/or novel markers on the same specimens and c) identifying new diseases/therapy indications for ex isting and optimised assays. Champ scientifique natural sciencesbiological sciencescell biologycell signalingnatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesclinical medicineoncologybreast cancermedical and health sciencesclinical medicineoncologyleukemianatural sciencesbiological scienceshistology Programme(s) FP6-MOBILITY - Human resources and Mobility in the specific programme for research, technological development and demonstration "Structuring the European Research Area" under the Sixth Framework Programme 2002-2006 Thème(s) MOBILITY-1.3 - Marie Curie Host Fellowships - Transfer of knowledge (TOK) Appel à propositions FP6-2002-MOBILITY-3 Voir d’autres projets de cet appel Régime de financement TOK - Marie Curie actions-Transfer of Knowledge Coordinateur DAKOCYTOMATION DENMARK A/S Contribution de l’UE Aucune donnée Adresse Produktionsvej, 42 GLOSTRUP Danemark Voir sur la carte Coût total Aucune donnée Participants (1) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire UNIVERSITY OF GLASGOW. Royaume-Uni Contribution de l’UE Aucune donnée Adresse University Avenue GLASGOW Voir sur la carte Coût total Aucune donnée